After two months of supplementation with Mirtogenol®, the mean IOP decreased from a baseline of 25.2 mmHg to 22.2 mmHg. Nineteen of the twenty patients taking Mirtogenol had a decreased IOP after three months. No side effects were observed. Ocular blood flow improved. Conclusions
The results of this study indicate that Mirtogenol® may represent a safe preventative intervention for lowering the risk for developing symptomatic glaucoma by controlling IOP and improving ocular blood flow.